ConductScience.org, home

Comparison · NCT01526889-8bbc14c6

LFG316 vs Conventional Therapy: Number of Participants With Remission in Study Eye - Treatment Period

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. LFG316 vs Conventional Therapy: Number of Participants With Remission in Study Eye - Treatment Period. Trial comparisons, record NCT01526889-8bbc14c6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01526889-8bbc14c6

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1110.0310.328wilson
Risk in group 200.00000000000000005550.354wilson
Risk difference, group 1 minus group 20.111-0.2520.328newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one more participant with the outcome on LFG316 than on Conventional Therapy9from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1LFG316LFG316 administered intravitreally218OG000
Group 2Conventional TherapyConventional treatment was selected by the investigator07OG001

Outcome

Type
PRIMARY
Title
Number of Participants With Remission in Study Eye - Treatment Period
Description
Remission (complete response) was defined as any patient who had:~* a vitreous haze score of 0 or 0.5 (scale of 0 to 4) in the study eye, AND~* an anterior chamber cell score of 0 (scale of 0 to 4), AND~* no chorioretinal lesions in the study eye, AND~* was off all immune modulatory therapy (systemic, corticosteroids and topical), AND~* without any worsening of uveitis during the trial.
Time frame
Day 85 (end of study)
Population
Efficacy 1 analysis set

Source ClinicalTrials.gov

Trial

Title
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
NCT number
NCT01526889
Phases
PHASE2
Conditions
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis
Interventions
LFG316, Conventional Therapy
Lead sponsor
Novartis Pharmaceuticals
Results first posted
2018-10-31

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01526889-8bbc14c6